[go: up one dir, main page]

AR059358A1 - Formulaciones farmaceuticas - Google Patents

Formulaciones farmaceuticas

Info

Publication number
AR059358A1
AR059358A1 ARP070100513A ARP070100513A AR059358A1 AR 059358 A1 AR059358 A1 AR 059358A1 AR P070100513 A ARP070100513 A AR P070100513A AR P070100513 A ARP070100513 A AR P070100513A AR 059358 A1 AR059358 A1 AR 059358A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical formulations
aqueous carrier
polymer
pleconaryl
administration
Prior art date
Application number
ARP070100513A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38121739&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059358(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR059358A1 publication Critical patent/AR059358A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un medicamento adecuado para la administracion como un inhalante nasal que incluye un portador acuoso y suspendido en el mismo pleconaril particulado, incluyendo el portador acuoso una composicion tixotropica que incluye celulosa microcristalina y un polímero seleccionado de una carboxialquilcelulosa de metal alcalino, un polímero de polivinilpirrolidona, y las mezclas de los mismos
ARP070100513A 2006-02-09 2007-02-07 Formulaciones farmaceuticas AR059358A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77192006P 2006-02-09 2006-02-09

Publications (1)

Publication Number Publication Date
AR059358A1 true AR059358A1 (es) 2008-03-26

Family

ID=38121739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100513A AR059358A1 (es) 2006-02-09 2007-02-07 Formulaciones farmaceuticas

Country Status (9)

Country Link
US (2) US20070202055A1 (es)
EP (1) EP1981475A2 (es)
JP (2) JP2009526063A (es)
AR (1) AR059358A1 (es)
CA (1) CA2641604A1 (es)
MX (1) MX2008010351A (es)
PE (1) PE20071250A1 (es)
TW (1) TW200806338A (es)
WO (1) WO2007095041A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043253A1 (en) * 2003-08-19 2005-02-24 Cook Bradley R. Use of wound healing compositions for prevention of infections and allergies
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
CA2641605A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations
WO2008157092A1 (en) 2007-06-20 2008-12-24 The Trustees Of Columbia University In The City Of New York Bio-film resistant surfaces
US9687429B2 (en) 2007-06-20 2017-06-27 The Trustees Of Columbia University In The City Of New York Antimicrobial compositions containing low concentrations of botanicals
US9981069B2 (en) 2007-06-20 2018-05-29 The Trustees Of Columbia University In The City Of New York Bio-film resistant surfaces
US9511040B2 (en) 2007-06-20 2016-12-06 The Trustees Of Columbia University In The City Of New York Skin and surface disinfectant compositions containing botanicals
CA2702094C (en) 2007-10-10 2018-05-01 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
TW201016215A (en) * 2008-07-17 2010-05-01 Schering Corp Compositions and uses of antiviral active pharmaceutical agents
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
PL2435024T3 (pl) * 2009-05-29 2017-01-31 Pearl Therapeutics, Inc. Dostarczanie substancji czynnych do dróg oddechowych oraz powiązane sposoby i systemy
AU2010266325B2 (en) * 2009-06-30 2016-01-07 The Trustees Of Columbia University In The City Of New York Antimicrobial/preservative compositions comprising botanicals
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
CN103732213A (zh) 2011-06-07 2014-04-16 帕里昂科学公司 治疗方法
ES2762405T3 (es) 2011-11-03 2020-05-25 Univ Columbia Composición con actividad antimicrobiana sostenida
US9968101B2 (en) 2011-11-03 2018-05-15 The Trustees Of Columbia University In The City Of New York Botanical antimicrobial compositions
CN102441006B (zh) * 2011-12-01 2016-06-01 刘学武 一种含二氧化氯的生发溶液及其制备和使用方法
TW201330856A (zh) 2011-12-06 2013-08-01 Univ Columbia 廣效性的天然防腐組成物
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
PT3043773T (pt) * 2013-09-13 2021-10-04 Glenmark Specialty Sa Composição farmacêutica de dose fixa estável composta por mometasona e olopatadina para administração nasal
EP3065550A4 (en) * 2013-11-08 2018-01-17 Antivirus Therapeutics Methods and compositions for treating sepsis
AU2015327762C1 (en) * 2014-10-03 2020-10-22 Lachesis Biosciences Limited Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders
CN104814960A (zh) * 2015-04-14 2015-08-05 沈阳药科大学 复方抗感冒药组合物及其用途
GB2581344B (en) * 2019-02-11 2023-05-24 Reckitt Benckiser Health Ltd Novel composition
AU2021338957A1 (en) * 2020-09-08 2023-05-25 Altamira Medica, Ag Compositions for preventing infection
IL303351A (en) * 2020-12-11 2023-08-01 Avaca Pharma Private Ltd A composition comprising fexofenadine
CN112546007A (zh) * 2020-12-31 2021-03-26 浙江诺得药业有限公司 一种含有孟鲁司特钠的口服固体片剂及其制备方法
CN118718184A (zh) * 2023-03-29 2024-10-01 深圳市合元科技有限公司 可用于电子雾化器雾化的液体制剂、筒以及气溶胶生成系统

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5349068A (en) * 1992-04-15 1994-09-20 Sterling Winthrop Inc. 1,2,4-oxadiazolyl-phenoxyalkylisoxazoles and their use as antiviral agents
US6565832B1 (en) * 2000-01-31 2003-05-20 Schering-Plough Healthcare Products, Inc. Spray composition with reduced dripping
AU2003208967A1 (en) * 2002-02-04 2003-09-02 Pharmacia Corporation A combination for treating cold and cough
CA2475971A1 (en) * 2002-02-14 2003-08-21 Viropharma Incorporated Methods of reducing rhinovirus contagion and related compositions
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US20040045546A1 (en) * 2002-09-05 2004-03-11 Peirce Management, Llc Pharmaceutical delivery system for oral inhalation through nebulization consisting of inert substrate impregnated with substance (S) to be solubilized or suspended prior to use
DE602004014728D1 (de) * 2003-02-21 2008-08-14 Apodemus Ab Behandlung von durch das ljungan-virus ausgelösten erkrankungen durch verwendung von pleconaril
WO2004093870A1 (en) * 2003-03-20 2004-11-04 Pharmacia Corporation Treatment and prevention of otic disorders
US20050009782A1 (en) * 2003-07-09 2005-01-13 Comper Wayne D. Antiviral charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and methods of use thereof
EP1718315A4 (en) * 2004-02-06 2008-08-13 Univ Monash HIGH DOSE USE OF SULFATED POLYSACCHARIDES IN SHORT INTERVALS FOR THE TREATMENT OF INFECTIONS
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US20060030550A1 (en) * 2004-08-04 2006-02-09 Lithgow Theodore L Pharmaceutical formulations
CA2641605A1 (en) * 2006-02-09 2007-08-23 Schering Corporation Pharmaceutical formulations

Also Published As

Publication number Publication date
MX2008010351A (es) 2008-10-31
US20090221541A1 (en) 2009-09-03
PE20071250A1 (es) 2008-01-14
WO2007095041A3 (en) 2008-05-08
EP1981475A2 (en) 2008-10-22
US20070202055A1 (en) 2007-08-30
WO2007095041A2 (en) 2007-08-23
JP2009526063A (ja) 2009-07-16
TW200806338A (en) 2008-02-01
CA2641604A1 (en) 2007-08-23
JP2009102425A (ja) 2009-05-14

Similar Documents

Publication Publication Date Title
AR059358A1 (es) Formulaciones farmaceuticas
MX2009010289A (es) Composiciones para administracion nasal.
ECSP088666A (es) Derivados de las benzamidas y heteroarenos
AR059359A1 (es) Formulaciones farmaceuticas que contienen pleconaril
UY30166A1 (es) Nuevas arildihidroisoquinolinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos
CL2009001248A1 (es) Compuestos derivados de indazolilo sustituido con fenilo, que actúan como moduladores de glucocorticoides; composición y combinación farmacéutica que comprenden a uno de los compuestos; y uso de los compuestos en la preparación de medicamentos para el tratamiento de enfermedades inflamatorias y respiratorias.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
SV2010003451A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
UY33201A (es) Compuestos de pirazol como antagonistas de crth2.
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CL2008001301A1 (es) Compuestos derivados de heterociclos de nitrogeno; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de una condicion inflamatoria o alergica, tal como una enfermedad inflamatoria u obstructiva de las vias respiratorias mediada por el bloqueo del canal de sodio epitelial.
CR20110599A (es) Composiciones farmacéuticamente activas que comprenden moduladores de estrés oxidativo (osm), nuevas entidades químicas, composiciones y usos
AR067309A1 (es) Formulaciones farmaceuticas que contienen derivados de acido lipoico
UY31456A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
BR112015018095A2 (pt) moduladores de receptor nmda de espiro-lactama e usos dos mesmos
UY30165A1 (es) Nuevas arildihidroisoquinolinonas sustituidas con aminolcoholes, procedimiento para su preparación y su uso como medicamentos
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
UY30163A1 (es) Nuevas ariltienopirimidinonas sustituidas con azaciclilo, procedimiento para su preparación y su uso como medicamentos
NI201500163A (es) Composiciones, métodos y sistemas para el suministro por vía respiratoria de tres o más agentes activos.
GT201200304A (es) Composiciones farmacéuticas que comprenden hidromorfona y naloxona
AR059357A1 (es) Formulaciones farmaceuticas
NO20082097L (no) Farmasoytiske sammensetninger
CL2011003327A1 (es) Composicion farmaceutica que comprende finafloxacina y un agente antiinflamatorio; uso en el tratamiento de infecciones oftalmicas, oticas o nasales.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal